SAB Member ILC Research
Our Scientific Advisory Board (SAB) not only helps ensure that information developed and shared by us is current, relevant, and accurate, but also performs their own ILC research.
The Lobular Breast Cancer Alliance’s (LBCA) scientific advisors are an internationally renowned group of clinicians and scientists with expertise in ILC research. Below are several members’ most recent research studies. You can find a complete collection of ILC research from our SAB members and others in our ILC Publications Library.
Recent Studies by Scientific Advisory Board Members
Rita Mukhtar, MD, recently authored The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study, which appeared in the Annals of Surgical Oncology. Dr. Mukhtar noted, “This study used the National Cancer Database to see whether chemotherapy was associated with a survival benefit in patients with 1-3 positive nodes and Oncotype Recurrence Score ≤25. Interestingly in unadjusted analysis of those under the age of 50, chemotherapy was not associated with improved survival in patients with ILC. The application of trial results such as RxPonder to pre-menopausal women with ILC needs to be studied.”
Jason Mouabbi, MD, had his review Invasive lobular carcinoma: an understudied emergent subtype of breast cancer from Breast Cancer Research and Treatment appear in Breast Cancer Research and Treatment.
Matthew Sikora, PhD and Rebecca Riggins, PhD were authors of Unlocking the Mysteries of Lobular Breast Cancer Biology Needs the Right Combination of Preclinical Models published in AACR Journals.
Congratulations to our SAB members on their latest work.